Labcorp (LH) Q2 FY26 earnings call

Labcorp delivered a robust second quarter, marked by solid revenue growth and significant margin expansion across both Diagnostics and Biopharma Laboratory Services segments. The company raised its full-year revenue and adjusted EPS guidance, driven by strong organic performance, strategic acquisitions, and operating efficiencies. Labcorp continues to advance its strategic priorities, focusing on specialty testing, health system partnerships, and leveraging technology to enhance customer experience and productivity, while actively managing capital deployment.